Enhancing Process Development With Viral Clearance: mAb Purification With A Weak AEX-HIC Chromatography Resin

Optimize your biopharmaceutical manufacturing and avoid expensive process overhauls by prioritizing viral clearance assessment early in development. This on-demand webinar delves into a study featuring the Nuvia wPrime 2A mixed-mode resin. See firsthand how this advanced media, tested under various pH conditions with co-spiked viruses, achieved no residual infectivity in end products.

This session also covers practical considerations for developing a monoclonal antibody (mAb) purification process with superior impurity clearance. Discover how to enhance your viral clearance and purification. Watch the webinar now.